PTGES3 Covalent Inhibitors for Blocking Androgen Receptor Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate cancer, such as androgen deprivation and AR antagonists, have limitations, and there is a need for alternative therapeutic strategies that target the interaction between prostaglandin E synthase 3 (PTGES3) and the androgen receptor (AR) to effectively inhibit prostate cancer progression.
Innovation Solution
Development of PTGES3 inhibitors that form a covalent bond with a cysteine residue, specifically Cys76, to block the interaction between PTGES3 and AR, thereby disrupting AR signaling and inhibiting prostate cancer progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (androgen deprivation and AR antagonists) are used, then prostate cancer treatment is achieved, but treatment limitations and resistance develop
Solution Approach 1:
The patent introduces PTGES3 as an intermediary target between androgen receptor signaling and cancer progression. By inhibiting PTGES3, the compound disrupts the interaction between PTGES3 and AR, creating a new therapeutic pathway that overcomes limitations of direct AR targeting alone
Solution Approach 2:
The invention changes the therapeutic parameter from direct AR modulation to PTGES3 inhibition. The compound modifies the biochemical environment by blocking PTGES3-AR interaction, thereby altering the signaling parameters and achieving treatment effects that conventional AR-targeted therapies cannot achieve alone
2Reliability
If PTGES3-AR interaction is blocked, then AR signaling is suppressed and cancer progression is inhibited, but compound specificity and selectivity must be maintained
Solution Approach 1:
The patent applies local quality by designing a compound with specific structural features (moieties) that selectively interact with a specific cysteine residue (Cys76) in PTGES3. This localized interaction ensures high specificity for the PTGES3-AR interface while avoiding off-target effects
Solution Approach 2:
The invention uses structural copying principles where the compound mimics or complements the PTGES3-AR interaction interface. By designing molecular structures that replicate the specific binding geometry and chemical interactions at the Cys76 site, the compound achieves selective disruption of the interaction without affecting other proteins
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PTGES3 inhibitors effectively disrupt the PTGES3-AR interaction, reducing AR protein levels, suppressing AR target gene expression, and inhibiting the growth of AR-dependent prostate cancer cells, while being permeable and specific to AR+ cell lines.
Implementation Method 1
The PTGES3 inhibitors has a moiety that can form a covalent bond with a thiol group, for example, of a cysteine residue of PTGES3
Data Source
AI summary
Provided are compounds for inhibiting prostaglandin E synthase 3 (PTGES3) along with methods of treating prostate cancer by administering such compounds to a subject. The PTGES3 inhibitors has a moiety that can form a covalent bond with a thiol group, for example, of a cysteine residue of PTGES3. By forming such a bond, the inhibitor can block a site on PTGES3 that is involved with the interaction between PTGES3 and androgen receptor (AR). Since the progression of prostate cancer can depend on AR activity, blocking the interaction of PTGES3 and AR can be used to treat prostate cancer.